Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 209 of the 211 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. However, GLP-1 is also produced in the brain and displays a critical role in neuroprotection and inflammation by activating the GLP-1 receptor signaling pathways. Several studies in vivo and in vitro using preclinical models of neurodegenerative diseases show that GLP-1R activation has anti-inflammatory properties. This review explores the molecular mechanistic action of GLP-1 RAS in relation to inflammation in the brain. These findings update our knowledge of the potential benefits of GLP-1RAS actions in reducing the inflammatory response. These molecules emerge as a potential therapeutic tool in treating neurodegenerative diseases and neuroinflammatory pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic processing of proglucagon. NTS: nucleus of the solitary tract; GRPP: glicentin-related polypeptide; IP-1: intervening peptide-1; IP-2: intervening peptide-2; GLP-1: glucagon-like peptide-1; GLP-2: glucagon-like peptide-2; MPGF: major proglucagon fragment; PCSK1: prohormone convertase 1/3; PCSK2: prohormone convertase 2. Modified from [36]. Created with Biorender.com.](https://figures.cochat.ai/paper-figures/b03e4d8dfc0940aca0935cc5c49966ed/anti-inflammatory-effects-of-glp-1-receptor-activation-in-the-brain-in-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs can alleviate neuroinflammation by acting on the nervous system, thereby offering additional relief from pain in patients.6,409,410”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs play a neuroprotective role in neurons by facilitating neuronal survival and promoting neuronal growth, thereby preserving the structural and functional integrity of synapses.6,14”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs are anti-inflammatory because they control the signals that immune cells send and receive.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Although it is well established that GLP-1RA’s anti-inflammatory effects originate from their impact on immune cell signaling, additional in-depth investigation into the underlying molecular pathways is required.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs may modulate inflammatory responses since GLP-1 receptors are present in immune cells such as macrophages, monocytes, and lymphocytes.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Neural regulation of endocrine and autonomic stress responses
Ulrich-Lai, Y. M., & Herman, J. P. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2647 · Cited by 3,318 · cited 2×
“Other areas of the brainstem that control the autonomic function including the limbic forebrain regions [36,48,50], areas of the mesolimbic reward system related to control of feeding and motivation to feed [36,51,52], or structures implicated in the regulation of the stress response and the HPA axis, learning and mem…”
BackgroundKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“The L-cells secrete GLP-1 at low basal levels in the fasting or interprandial state [37], and predominantly express the prohormone convertase 1 (PC1/3; Pcsk1).”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710 · cited 1×
“Microglia are the principal resident immune cells of the brain and are involved in homeostasis and host defense against pathogens and CNS disorders [5].”
BackgroundLock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640 · cited 13×
“Following the breakdown of BBB, activation of Th1, Th17, and γδ T cells enter the brain and spinal cord [128].”
BackgroundInfluentialSingle-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M. K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.020 · Cited by 1,550
An overview of the immune system
Parkin, J., & Cohen, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04904-7 · Cited by 1,460 · cited 1×
“It is a significant target for developing treatment strategies, opening a therapeutical window of opportunity to change many of these disorders with similar approaches [20].”
BackgroundSamii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 2×
“Astrocytes’ activation may be beneficial, promoting tissue repair and homeostasis, or detrimental, exacerbating inflammatory reactions and tissue damage, depending on the stimuli’ nature [14,15].”
BackgroundThe far-reaching scope of neuroinflammation after traumatic brain injury
Simon, D. W., McGeachy, M. J., Bayır, H., Clark, R. S. B., Loane, D. J., & Kochanek, P. M. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.13 · Cited by 1,190
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Immortalization of murine microglial cells by a v-raf / v-myc carrying retrovirus
Blasi, E., Barluzzi, R., Bocchini, V., Mazzolla, R., & Bistoni, F. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90073-v · Cited by 1,053
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 1×
“The GLP-1 receptor forms part of the secretin calcitonin and the parathyroid family of G-coupled receptors (GPCRs) [67].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“The two N-terminally truncated products, a glycine extended peptide GLP-1(7–37) and GLP-1(7–36) amide, are recognized by the pancreatic receptor, and are the active species in vivo [40].”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“No GLP-1R was seen in primate liver and thyroid [73,74].”
BackgroundDendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis
Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., Noelle, R. J., & Becher, B. (2005) · Nature Medicine · doi:10.1038/nm1197 · Cited by 862 · cited 1×
“Although there are no antigen-presenting cells within the CNS parenchyma, this role can be performed by dendritic cells at the interface of the CNS and the immune system in association with blood vessels [2].”
BackgroundRegulation of innate immune responses in the brain
Rivest, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2565 · Cited by 843
Astrocytes from familial and sporadic ALS patients are toxic to motor neurons
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M. J., Foust, K. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1957 · Cited by 782
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 9×
“Non-acylated, non-PEGylated incretin receptor agonists such as Liraglutide, semaglutide, and Peptide 18 enter the brain [95,96].”
BackgroundInfluentialMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Revisiting the Mechanisms of CNS Immune Privilege
Louveau, A., Harris, T. H., & Kipnis, J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.006 · Cited by 682
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 5×
“Different pharmacological agents, GLP-1 derivatives, with extended halflife and improved bioavailability, have been developed in the last few years for treating type 2 diabetes and obesity [25,55,56].”
BackgroundInfluentialInsights into G Protein Structure, Function, and Regulation
Cabrera-Vera, T. M., Vanhauwe, J., Thomas, T. O., Medkova, M., Preininger, A., Mazzoni, M. R., & Hamm, H. E. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0026 · Cited by 661
Chiu, I. M., Morimoto, E. T. A., Goodarzi, H., Liao, J. T., O’Keeffe, S., Phatnani, H. P., Muratet, M., Carroll, M. C., Levy, S., Tavazoie, S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.06.018 · Cited by 651
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
Astrocyte-neuron metabolic cooperation shapes brain activity
Bonvento, G., & Bolaños, J. P. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.006 · Cited by 580 · cited 1×
“This includes synapse formation and maturation, ion and neurotransmitter homeostasis, blood-brain barrier maintenance, and neuronal metabolic support [12,13].”
BackgroundMicroglia-Astrocyte Crosstalk: An Intimate Molecular Conversation
Jha, M. K., Jo, M., Kim, J.-H., & Suk, K. (2019) · The Neuroscientist · doi:10.1177/1073858418783959 · Cited by 579 · cited 5×
“Microglia are the first cells to respond to CNS insults, followed by reactive astrocytosis [15].”
BackgroundInfluentialGlial influence on the blood brain barrier
Alvarez, J. I., Katayama, T., & Prat, A. (2013) · Glia · doi:10.1002/glia.22575 · Cited by 544 · cited 1×
“Moreover, the blood-brain barrier is part of the innate immune defense against pathogens entering the CNS [3,4].”
BackgroundAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530 · cited 1×
“Furthermore, GLP-1 shows anti-inflammatory effects on pancreatic islets and adipose tissue [109,110], also in the liver, the vascular system, including aorta and vein endothelial cells, kidney, lung, testis, and skin, by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues…”
BackgroundExenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets
Han, M. H., Hwang, S.-I., Roy, D. B., Lundgren, D. H., Price, J. V., Ousman, S. S., Fernald, G. H., Gerlitz, B., Robinson, W. H., Baranzini, S. E., et al. (2008) · Nature · doi:10.1038/nature06559 · Cited by 516
The cuprizone animal model: new insights into an old story
Kipp, M., Clarner, T., Dang, J., Copray, S., & Beyer, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0591-3 · Cited by 481
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
NLRP3 inflammasome in neurological diseases, from functions to therapies
Song, L., Pei, L., Yao, S., Wu, Y., & Shang, Y. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00063 · Cited by 467
Immunoneuropsychiatry — novel perspectives on brain disorders
Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0174-4 · Cited by 458
Crosstalk Between Astrocytes and Microglia: An Overview
Matejuk, A., & Ransohoff, R. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01416 · Cited by 445
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
Bettcher, B. M., Tansey, M. G., Dorothée, G., & Heneka, M. T. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00549-x · Cited by 427
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406 · cited 1×
“Moreover, GLP-1R is distributed in the thymus and spleen, and various immune cells such as T cells, natural killer T cells, monocytes, and macrophages can regulate peripheral Treg cell proportion in rodents and humans [98].”
BackgroundEvolution of Inflammatory Diseases
Okin, D., & Medzhitov, R. (2012) · Current Biology · doi:10.1016/j.cub.2012.07.029 · Cited by 388
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
AMP-activated protein kinase: new regulation, new roles?
Carling, D., Thornton, C., Woods, A., & Sanders, M. J. (2012) · Biochemical Journal · doi:10.1042/bj20120546 · Cited by 379
Microglia: Agents of the CNS Pro-Inflammatory Response
Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365 · cited 1×
“Microglia cells also have a prominent role in the etiology and progression of different neurodegenerative diseases [8].”
BackgroundThe Role of Astrocytes in Multiple Sclerosis
Ponath, G., Park, C., & Pitt, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00217 · Cited by 359
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353 · cited 1×
“This demonstrates that there may be differences in GLP-1 effects since GLP-1R expression may vary among species [32,85,86].”
BackgroundHow does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Alzheimer’s disease and insulin resistance: translating basic science into clinical applications
De Felice, F. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 330
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Larsen, P. J. (1997) · Endocrinology · doi:10.1210/en.138.10.4445 · Cited by 316 · cited 1×
“It is synthesized after cell-specific post-translational processing by the prohormone convertases (Pcsk1) (Figure 1) [42,43].”
BackgroundGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · cited 1×
“No GLP-1R was seen in primate liver and thyroid [73,74].”
BackgroundGlaesner, W., Mark Vick, A., Millican, R., Ellis, B., Tschang, S., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305 · cited 1×
“(iii) Linkage of two GLP-1 molecules via the Fc fragment of a monoclonal antibody (IgG4), as was applied for dulaglutide [62,63].”
BackgroundAlvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., García‐Cuartero, B., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., De Cáceres, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 305 · cited 1×
“In the human brain, in situ hybridization histochemistry revealed specific labeling for GLP-1 receptor mRNA in several brain areas like the cerebral cortex (especially in the occipital and frontal cortex), hypothalamus (mainly the ventromedial and arcuate nuclei), hippocampus, thalamus, caudate-putamen, and globus pal…”
BackgroundPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302 · cited 14×
“The primary source of endogenous GLP-1 within the brain is a population of preproglucagon (PPG) neurons in the caudal portion of the nucleus of the solitary tract (NTS).”
BackgroundInfluentialRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · cited 1×
“mRNA transcripts of the receptor were widely distributed in peripheral tissues and the central nervous system (CNS) [69].”
BackgroundGLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289 · cited 3×
“They are well tolerated, have little and very mild secondary effects, and are suitable to be administered in the long-term as they should be therapeutically used in neuropathology [58].”
BackgroundInfluentialCentral effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263
Neutrophil-related factors as biomarkers in EAE and MS
Rumble, J. M., Huber, A. K., Krishnamoorthy, G., Srinivasan, A., Giles, D. A., Zhang, X., Wang, L., & Segal, B. M. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141015 · Cited by 262
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS)
Glatigny, S., & Bettelli, E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028977 · Cited by 247
Batista, A. F., Forny‐Germano, L., Clarke, J. R., Lyra e Silva, N. M., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246
Brambilla, R. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01980-7 · Cited by 246
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Kahles, F., Meyer, C., Möllmann, J., Diebold, S., Findeisen, H. M., Lebherz, C., Trautwein, C., Koch, A., Tacke, F., Marx, N., et al. (2014) · Diabetes · doi:10.2337/db14-0100 · Cited by 212
Sex differences in movement disorders
Meoni, S., Macerollo, A., & Moro, E. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0294-x · Cited by 207
Neidigh, J. W., Fesinmeyer, R. M., Prickett, K. S., & Andersen, N. H. (2001) · Biochemistry · doi:10.1021/bi010902s · Cited by 204 · cited 1×
“Exenatide (Byetta® and Bydureon®, AstraZeneca, Cambridge, UK), a synthetic 39-amino acid peptide that was the first GLP-1 RA approved for clinical use [25,59,60] or Lixisenatide (Sanofi, Paris, France), is an analog of exenatide, with comparable pharmacokinetic properties [25,61].”
BackgroundAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199 · cited 2×
“Different pharm cologic l ag nts, GLP-1 derivatives, with extend d halflife and improved bioavailability, h ve been developed in th last few years for tr ating type 2 diabetes and obesity [25,55,56].”
BackgroundNeuroinflammation — a common thread in neurological disorders
Gilhus, N. E., & Deuschl, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0227-8 · Cited by 198 · cited 1×
“Inflammatory processes influence most neurological disorders, even those whose primary etiology is not inflammatory [16].”
BackgroundHeppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196 · cited 1×
“Similarly, in non-human primates, the GLP-1R mRNA and protein expression present similar distribution in the CNS to rodents [88].”
BackgroundAMPK activation: Role in the signaling pathways of neuroinflammation and neurodegeneration
Peixoto, C. A., Oliveira, W. H. D., Araújo, S. M. D. R., & Nunes, A. K. S. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.013 · Cited by 196
Preproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194 · cited 1×
“Other areas of the brainstem that control the autonomic function including the limbic forebrain regions [36,48,50], areas of the mesolimbic reward system related to control of feeding and motivation to feed [36,51,52], or structures implicated in the regulation of the stress response and the HPA axis, learning and mem…”
BackgroundPark, J.-S., Kam, T.-I., Lee, S., Park, H., Oh, Y., Kwon, S.-H., Song, J.-J., Kim, D., Kim, H., Jhaldiyal, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01180-z · Cited by 192
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188 · cited 2×
“Non-acylated, non-PEGylated incretin receptor agonists such as Liraglutide, semaglutide, and Peptide 18 enter the brain [95,96].”
BackgroundBrain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180 · cited 2×
“These molecules bind to GLP-1R and activate downstream signaling effects on cell growth and repair equivalent to GLP-1 [57].”
BackgroundRomaní-Pérez, M., Outeiriño-Iglesias, V., Moya, C. M., Santisteban, P., González-Matías, L. C., Vigo, E., & Mallo, F. (2015) · Endocrinology · doi:10.1210/en.2014-1685 · Cited by 178
Self-citationInnate and adaptive immune responses in the CNS
Waisman, A., Liblau, R., & Becher, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00141-6 · Cited by 173 · cited 3×
“Two cell types: microglia and astrocytes are involved in the immune defense in the parenchyma [4].”
BackgroundVendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O’Halloran, D., Hölscher, C., & O’Neill, C. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8199-5 · Cited by 168
Nguyen, A. T., Mandard, S., Dray, C., Deckert, V., Valet, P., Besnard, P., Drucker, D. J., Lagrost, L., & Grober, J. (2014) · Diabetes · doi:10.2337/db13-0903 · Cited by 161
AMPK in the brain: its roles in glucose and neural metabolism
Muraleedharan, R., & Dasgupta, B. (2022) · The FEBS Journal · doi:10.1111/febs.16151 · Cited by 160
Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)
Barclay, W., & Shinohara, M. L. (2017) · Brain Pathology · doi:10.1111/bpa.12477 · Cited by 152
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.07.003 · Cited by 148
Progranulin is Neurotrophic In Vivo and Protects against a Mutant TDP-43 Induced Axonopathy
Laird, A. S., Van Hoecke, A., De Muynck, L., Timmers, M., Van Den Bosch, L., Van Damme, P., & Robberecht, W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013368 · Cited by 147
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146 · cited 7×
“, Indianapolis, IN), and albiglutide (GlaxoSmithKline, London, UK) [62].”
BackgroundInfluentialTai, J., Liu, W., Li, Y., Li, L., & Hölscher, C. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.012 · Cited by 145
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Hölscher, C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15508 · Cited by 145 · cited 1×
“to trigger an inflammatory response in the brain to increase its density, which indicates that it plays a role in controlling inflammation [22,91].”
BackgroundHui, H., Farilla, L., Merkel, P., & Perfetti, R. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460863 · Cited by 143 · cited 1×
“The short half-life of GLP-1 is limited in its therapeutic use, since it is rapidly metabolized and inactivated by the dipeptidyl peptidase IV after release to the extracellular space [25,54].”
BackgroundRentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Lobsiger, C. S., Boillée, S., & Cleveland, D. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702230104 · Cited by 140
Ast, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Koszegi, Z., Bacon, A., Jones, B. J., Lucey, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14309-w · Cited by 140
Shirazi, R., Palsdottir, V., Collander, J., Anesten, F., Vogel, H., Langlet, F., Jaschke, A., Schürmann, A., Prévot, V., Shao, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306799110 · Cited by 137
Lee, C., Jeon, S. J., Cho, K. S., Moon, E., Sapkota, A., Jun, H., Ryu, J. H., & Choi, J. W. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0550-2 · Cited by 136
McClean, P. L., Jalewa, J., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.024 · Cited by 135
Alhadeff, A. L., Baird, J.-P., Swick, J., Hayes, M. R., & Grill, H. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.74 · Cited by 134 · cited 1×
“Other areas of the brainstem that control the autonomic function including the limbic forebrain regions [36,48,50], areas of the mesolimbic reward system related to control of feeding and motivation to feed [36,51,52], or structures implicated in the regulation of the stress response and the HPA axis, learning and mem…”
BackgroundAstrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance
Reiner, D. J., Mietlicki-Baase, E. G., McGrath, L. E., Zimmer, D. J., Bence, K. K., Sousa, G. L., Konanur, V. R., Krawczyk, J., Burk, D. H., Kanoski, S. E., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3579-15.2016 · Cited by 133 · cited 1×
“In the brain, the GLP-1 receptor is highly expressed differently in neurons and glial cells in several regions [24,90,91].”
BackgroundLi, Y., Chigurupati, S., Holloway, H. W., Mughal, M., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 132
Shi, L., Zhang, Z., Li, L., & Hölscher, C. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.032 · Cited by 123
TLR-stimulated IRAKM activates caspase-8 inflammasome in microglia and promotes neuroinflammation
Zhang, C.-J., Jiang, M., Zhou, H., Liu, W., Wang, C., Kang, Z., Han, B., Zhang, Q., Chen, X., Xiao, J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121901 · Cited by 121
Feng, P., Zhang, X., Li, D., Ji, C., Yuan, Z., Wang, R., Xue, G., Li, G., & Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.012 · Cited by 120
Thinking outside the box: non-canonical targets in multiple sclerosis
Bierhansl, L., Hartung, H.-P., Aktas, O., Ruck, T., Roden, M., & Meuth, S. G. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00477-5 · Cited by 117
Yuan, Z., Li, D., Feng, P., Xue, G., Ji, C., Li, G., & Hölscher, C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.06.029 · Cited by 116
Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1
Ugleholdt, R., Zhu, X., Deacon, C. F., Ørskov, C., Steiner, D. F., & Holst, J. J. (2004) · Endocrinology · doi:10.1210/en.2003-0801 · Cited by 115
Heiss, C. N., Mannerås-Holm, L., Lee, Y. S., Serrano-Lobo, J., Håkansson Gladh, A., Seeley, R. J., Drucker, D. J., Bäckhed, F., & Olofsson, L. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109163 · Cited by 114 · cited 1×
“In the hypothalamus, GLP1R is expressed in neurons, vascular cells, and in a population of astrocytes that express aquaporin, associated with astrocyte vascular end feet, but not in microglia [93,94].”
BackgroundGlucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu, H., Wiesenthal, S. R., MacDonald, P. E., McCall, R. H., Tchipashvili, V, Rashid, S., Satkunarajah, M., Irwin, D. M., Shi, Z. Q., Brubaker, P. L., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1045 · Cited by 113 · cited 1×
“This demonstrates that there may be differences in GLP-1 effects since GLP-1R expression may vary among species [32,85,86].”
BackgroundHuman epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes
Iacobellis, G., Camarena, V., Sant, D., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-109563 · Cited by 112
Elbaz, E. M., Senousy, M. A., El-Tanbouly, D. M., & Sayed, R. H. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.035 · Cited by 112
Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets
Govindarajan, V., de Rivero Vaccari, J. P., & Keane, R. W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01944-9 · Cited by 110
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Song, S., Guo, R., Mehmood, A., Zhang, L., Yin, B., Yuan, C., Zhang, H., Guo, L., & Li, B. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13791 · Cited by 109
Proglucagon processing in islet and intestinal cell lines
Tucker, J. D., Dhanvantari, S., & Brubaker, P. L. (1996) · Regulatory Peptides · doi:10.1016/0167-0115(95)00167-0 · Cited by 106 · cited 1×
“In addition to GLP-1, proglucagon cleavage results in the liberation of glucagon-like peptide two (GLP-2), oxyntomodulin, glicentin and intervening peptide-2 (IP2) [36,38].”
BackgroundZhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104
Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing
Labandeira, C. M., Bau, A. F., Ron, D. A., Álvarez, E., Alba, P. V., Garma, J. L., & Rodriguez-Perez, A. I. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.332122 · Cited by 104
Drucker, D. J., Mojsov, S., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67561-1 · Cited by 103 · cited 1×
“GLP-1 is synthesized from the proglucagon gene after cell-specific post-translational processing by two members of the convertase subtilisin/kexin (PCSK) family (Figure 1) [35,36].”
BackgroundSex and estrogens alter the action of glucagon-like peptide-1 on reward
Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0059-9 · Cited by 102 · cited 2×
“In the operant conditioning task, in both non-deprived and food-restricted animals with more significant differences in the fed state [99], this gender difference is abrogated with ER antagonist in both sexes [99].”
BackgroundIon Channels and Receptors as Determinants of Microglial Function
Izquierdo, P., Attwell, D., & Madry, C. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.007 · Cited by 102
Outeiriño-Iglesias, V., Romaní-Pérez, M., González-Matías, L. C., Vigo, E., & Mallo, F. (2015) · Endocrinology · doi:10.1210/en.2014-1978 · Cited by 99
Self-citationChowen, J. A., & García‐Segura, L. M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111473 · Cited by 99
Gender Issues in Multiple Sclerosis
Schwendimann, R. N., & Alekseeva, N. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)79017-7 · Cited by 96
GLP-1/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis
Chen, J., Zhao, H., Ma, X., Zhang, Y., Lu, S., Wang, Y., Zong, C., Qin, D., Wang, Y., Yingfeng Yang, Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478872 · Cited by 94
Cao, L., Li, D., Feng, P., Li, L., Xue, G.-F., Li, G., & Hölscher, C. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000548 · Cited by 90
(2020) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-64123-6.00018-7 · Cited by 89
GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes
Gault, V. A., & Hölscher, C. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.017 · Cited by 86
Islet prohormone processing in health and disease
Chen, Y., Taylor, A. J., & Verchere, C. B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13401 · Cited by 86 · cited 2×
“They produce glucagon, glicentin-related pancreatic polypeptide (GRPP), the significant proglucagon fragment (MPGF), and intervening peptide-1 (IP-1) [36,39].”
BackgroundGlucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84 · cited 2×
“This demonstrates that there may be differences in GLP-1 effects since GLP-1R expression may vary among species [32,85,86].”
BackgroundMethodSelf-citationAmmar, R. A., Mohamed, A. F., Kamal, M. M., Safar, M. M., & Abdelkader, N. F. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00956-6 · Cited by 84
Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzík, M., Železná, B., Kuneš, J., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.002 · Cited by 82
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81 · cited 1×
“Exenatide (Byetta® and Bydureon®, AstraZeneca, Cambridge, UK), a synthetic 39-amino acid peptide that was the first GLP-1 RA approved for clinical use [25,59,60] or Lixisenatide (Sanofi, Paris, France), is an analog of exenatide, with comparable pharmacokinetic properties [25,61].”
BackgroundQian, Z., Chen, H., Xia, M., Chang, J., Li, X., Ye, S., Wu, S., Jiang, S., Bao, J., Wang, B., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68974 · Cited by 80 · cited 1×
“For example, in mice, GLP-1R is expressed in neurons and microglia cells but not in astrocytes in the spinal cord [92].”
BackgroundTorres-Ceja, B., & Olsen, M. L. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102550 · Cited by 79 · cited 1×
“This includes synapse formation and maturation, ion and neurotransmitter homeostasis, blood-brain barrier maintenance, and neuronal metabolic support [12,13].”
BackgroundGlucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
Insuela, D. B. R., & Carvalho, V. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.015 · Cited by 72
Fang, X., Tian, P., Zhao, X., Jiang, C., & Chen, T. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14694 · Cited by 72
Salles, G. N., Calió, M. L., Hölscher, C., Pacheco-Soares, C., Porcionatto, M., & Lobo, A. O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107813 · Cited by 71
Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 71 · cited 10×
“The primary source of endogenous GLP-1 within the brain is a population of preproglucagon (PPG) neurons in the caudal portion of the nucleus of the solitary tract (NTS).”
BackgroundInfluentialChowen, J. A., de Fonseca, F. R., Álvarez, E., Navarro, M. A., García‐Segura, L. M., & Blázquez, E. (1999) · Neuropeptides · doi:10.1054/npep.1999.0757 · Cited by 70 · cited 2×
“to trigger an inflammatory response in the brain to increase its density, which indicates that it plays a role in controlling inflammation [22,91].”
BackgroundAnti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P.-O., Ricordi, C., & Pastori, R. L. (2012) · Cell Transplantation · doi:10.3727/096368911x576027 · Cited by 67
Maskery, M., Goulding, E. M., Gengler, S., Melchiorsen, J. U., Rosenkilde, M. M., & Hölscher, C. (2020) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317520953041 · Cited by 66
Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0410-7 · Cited by 64 · cited 1×
“With regards to data from preregistration, clinical trials show that liraglutide exposure is about 32% higher in women than in men after adjusting for body weight [102,103]; and different pharmacokinetics have been described with a higher rate of drug degradation in men when compared with women [102,103].”
Cao, B., Zhang, Y., Chen, J., Wu, P., Dong, Y., & Wang, Y. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00879-1 · Cited by 62
Llewellyn-Smith, I. J., Gnanamanickam, G. J. E., Reimann, F., Gribble, F. M., & Trapp, S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.071 · Cited by 61 · cited 1×
“Other areas of the brainstem that control the autonomic function including the limbic forebrain regions [36,48,50], areas of the mesolimbic reward system related to control of feeding and motivation to feed [36,51,52], or structures implicated in the regulation of the stress response and the HPA axis, learning and mem…”
BackgroundGLP-1 receptor agonist ameliorates experimental lung fibrosis
Fandiño, J., Toba, L., González-Matías, L. C., Diz-Chaves, Y., & Mallo, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-74912-1 · Cited by 59 · cited 1×
“Furthermore, GLP-1 shows anti-inflammatory effects on pancreatic islets and adipose tissue [109,110], also in the liver, the vascular system, including aorta and vein endothelial cells, kidney, lung, testis, and skin, by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues…”
BackgroundSelf-citationFerreira, S. T. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12959 · Cited by 59
Zhang, M., Wu, Y., Gao, R., Chen, X., Chen, R., & Chen, Z. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111529 · Cited by 59
Lv, M., Xue, G., Cheng, H., Meng, P., Lian, X., Hölscher, C., & Li, D. (2021) · Brain and Behavior · doi:10.1002/brb3.2231 · Cited by 58
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54 · cited 3×
“In mice, GLP-1R is present in pancreatic acinar-, β-, and δ cells, but rarely in α cells [83].”
BackgroundMethodInfluentialCarranza-Naval, M. J., del Marco, A., Hierro-Bujalance, C., Alves-Martinez, P., Infante-Garcia, C., Vargas-Soria, M., Herrera, M., Barba-Cordoba, B., Atienza-Navarro, I., Lubian-Lopez, S., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.741923 · Cited by 54
Ejarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53
Romaní-Pérez, M., Outeiriño-Iglesias, V., Gil-Lozano, M., González-Matías, L. C., Mallo, F., & Vigo, E. (2013) · Endocrinology · doi:10.1210/en.2012-1786 · Cited by 51
Self-citationSynaptic Inputs to the Mouse Dorsal Vagal Complex and Its Resident Preproglucagon Neurons
Holt, M. K., Pomeranz, L. E., Beier, K. T., Reimann, F., Gribble, F. M., & Rinaman, L. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.2145-19.2019 · Cited by 51
Knippenberg, S., Thau, N., Schwabe, K., Dengler, R., Schambach, A., Hass, R., & Petri, S. (2011) · Neurodegenerative Diseases · doi:10.1159/000331327 · Cited by 50
Dynamic Responses of Microglia in Animal Models of Multiple Sclerosis
Plastini, M. J., Desu, H. L., & Brambilla, R. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00269 · Cited by 48 · cited 2×
“Microglia are activated by phenotypical morphological changes in response to injury or disease, increasing cell proliferation (Figure 3) [6,11].”
BackgroundChiou, H.-Y. C., Lin, M.-W., Hsiao, P.-J., Chen, C.-L., Chiao, S., Lin, T.-Y., Chen, Y.-C., Wu, D.-C., & Lin, M.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071584 · Cited by 47
Gharagozloo, M., Smith, M. D., Sotirchos, E. S., Jin, J., Meyers, K. R., Taylor, M., Garton, T. P., Bannon, R. N., Lord, H., Dawson, T. M., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01088-5 · Cited by 47
Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine
Colosimo, C., Iuliis, A. D., Montinaro, E., Fatati, G., & Plebani, M. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320965 · Cited by 47
Li, Y., Glotfelty, E. J., Karlsson, T., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47 · cited 1×
“However, in vitro studies have demonstrated that its metabolite, GLP-1(9–36), has protective effects in neuronal and microglial cell lines [41].”
BackgroundSmith, C., Patterson-Cross, R., Woodward, O., Lewis, J., Chiarugi, D., Merkle, F., Gribble, F., Reimann, F., & Adriaenssens, A. (2022) · Appetite · doi:10.1016/j.appet.2022.106022 · Cited by 47
The role of insulin-like growth factor 1 in ALS cell and mouse models: A mitochondrial protector
Wen, D., Cui, C., Duan, W., Wang, W., Wang, Y., Liu, Y., Li, Z., & Li, C. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.09.015 · Cited by 46
Stressing diabetes? The hidden links between insulinotropic peptides and the HPA axis
Diz-Chaves, Y., Gil-Lozano, M., Toba, L., Fandiño, J., Ogando, H., González-Matías, L. C., & Mallo, F. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0118 · Cited by 44
Self-citationSpinally projecting preproglucagon axons preferentially innervate sympathetic preganglionic neurons
Llewellyn-Smith, I. J., Marina, N., Manton, R. N., Reimann, F., Gribble, F. M., & Trapp, S. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.043 · Cited by 40
DellaValle, B., Brix, G. S., Brock, B., Gejl, M., Landau, A. M., Møller, A., Rungby, J., & Larsen, A. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00433 · Cited by 39
The supramammillary nucleus controls anxiety-like behavior; key role of GLP-1R
López-Ferreras, L., Eerola, K., Shevchouk, O. T., Richard, J. E., Nilsson, F. H., Jansson, L. E., Hayes, M. R., & Skibicka, K. P. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104720 · Cited by 39 · cited 2×
“Other areas of the brainstem that control the autonomic function including the limbic forebrain regions [36,48,50], areas of the mesolimbic reward system related to control of feeding and motivation to feed [36,51,52], or structures implicated in the regulation of the stress response and the HPA axis, learning and mem…”
BackgroundGLP-1 neurons form a local synaptic circuit within the rodent nucleus of the solitary tract
Card, J. P., Johnson, A. L., Llewellyn‐Smith, I. J., Zheng, H., Anand, R., Brierley, D. I., Trapp, S., & Rinaman, L. (2018) · Journal of Comparative Neurology · doi:10.1002/cne.24482 · Cited by 38
Diz-Chaves, Y., Toba, L., Fandiño, J., González-Matías, L. C., Garcia-Segura, L. M., & Mallo, F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1370-7 · Cited by 38 · cited 2×
“The treatment of food-restricted pregnant dams with liraglutide prevents this neuroinflammatory response, promoting the production of anti-inflammatory molecules and decreasing the number and reactivity of microglial cells and astrocytes only in males [101].”
BackgroundSelf-citationMéndez, M. M., Matter, H., Defoßa, E., Kurz, M. E., Lebreton, S., Li, Z., Lohmann, M., Löhn, M., Mors, H., Podeschwa, M. A. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01071 · Cited by 38
Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
Gray, S. M., Xin, Y., Ross, E. C., Chazotte, B. M., Capozzi, M. E., El, K., Svendsen, B., Ravn, P., Sloop, K. W., Tong, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014368 · Cited by 38 · cited 1×
“This was previously described using Glp1r reporter mice and a validated GLP-1R antibody, in which no expression of the receptor was observed in α-cells, and GLP-1R mRNA but not protein was detected in δ-cells [84].”
MethodLi, L., Zhang, L.-Y., Jin, Q.-Q., & Hölscher, C. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303045 · Cited by 38
Shandilya, A., & Mehan, S. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05328-6 · Cited by 37
Gender‐related issues in the pharmacology of new anti‐obesity drugs
Cataldi, M., Muscogiuri, G., Savastano, S., Barrea, L., Guida, B., Taglialatela, M., & Colao, A. (2019) · Obesity Reviews · doi:10.1111/obr.12805 · Cited by 36 · cited 2×
“With regards to data from preregistration, clinical trials show that liraglutide exposure is about 32% higher in women than in men after adjusting for body weight [102,103]; and different pharmacokinetics have been described with a higher rate of drug degradation in men when compared with women [102,103].”
BackgroundSargsyan, S. A., Blackburn, D. J., Barber, S. C., Großkreutz, J., Vos, K. J. D., Monk, P. N., & Shaw, P. J. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-91 · Cited by 35
Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., & Mallo, F. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2021.12.005 · Cited by 35 · cited 9×
“They produce glucagon, glicentin-related pancreatic polypeptide (GRPP), the significant proglucagon fragment (MPGF), and intervening peptide-1 (IP-1) [36,39].”
BackgroundInfluentialSelf-citationThiebaud, N., Gribble, F., Reimann, F., Trapp, S., & Fadool, D. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-51880-9 · Cited by 34
Cai, H.-Y., Yang, D., Qiao, J., Yang, J.-T., Wang, Z.-J., Wu, M.-N., Qi, J.-S., & Hölscher, C. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210256 · Cited by 34
Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis
Nelson, A. T., & Trotti, D. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01262-3 · Cited by 34
Sun, H. J., Knippenberg, S., Thau, N., Ragancokova, D., Körner, S., Huang, D., Dengler, R., Döhler, K. D., & Petri, S. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9900-9 · Cited by 30
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26 · cited 8×
“The primary source of endogenous GLP-1 within the brain is a population of preproglucagon (PPG) neurons in the caudal portion of the nucleus of the solitary tract (NTS).”
BackgroundInfluentialKeerie, A. F. A., Brown-Wright, H., Kirkland, I., Grierson, A. J., Alix, J. J. P., Hölscher, C., & Mead, R. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-96418-0 · Cited by 26
Astiz, M., Diz-Chaves, Y., & García‐Segura, L. M. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.07.008 · Cited by 25
Self-citationGil-Lozano, M., Romaní-Pérez, M., Outeiriño-Iglesias, V., Vigo, E., González-Matías, L. C., Brubaker, P. L., & Mallo, F. (2014) · Endocrinology · doi:10.1210/en.2013-1718 · Cited by 24
Self-citationWillard, F. S., Wainscott, D. B., Showalter, A. D., Stutsman, C., Ma, W., Cardona, G. R., Zink, R. W., Corkins, C. M., Chen, Q., Yumibe, N. P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00029 · Cited by 23 · cited 1×
“the endogenous ligand is present, thereby providing an opportunity to enhance the normal GLP-1 response selectively [64] Some of these PAMS interact with the less active form of GLP-1, potentiating the activity of GLP-1(9–36) by interacting with both the peptide and the receptor [64–66].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“24,35 Through their interactions with GLP-1RAs, immune cell signals are modulated inside the cell.”
BackgroundInfluentialGlucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
BackgroundMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Because the health benefits of obesity treatment generally outweigh these temporary challenges,”
Metadata
- Authors
- Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F.
- Affiliations
- Universidade de Vigo (ES)
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212 Vigo, Spain
- Corresponding author
- Diz-Chaves, Yolanda
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-24
- Volume
- 23
- Issue
- 17
- Pages
- 9583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9455625
- OpenAlex
- W4293001879
- Cited by
- 148
- References
- 211
- Citations by year
- 2026: 52 · 2025: 66 · 2024: 21 · 2023: 9
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Investigo Institutional repository of UVigo (Universidade de Vigo) (submittedVersion, cc-by)
- Funders
- European Union Grant Alehoop (H2020-BBIJTI-2019-887259, ED431G/02)
- Xunta de Galicia (Centro singular de Investigación de Galicia accreditation 2016–2019) (H2020-BBIJTI-2019-887259, ED431G/02)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, neuroinflammation, neurodegenerative diseases, neuroprotection, anti-inflammatory activity, brain, GLP-1 receptor signaling, therapeutic target
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Brain, Humans, Inflammation, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.